SCHEMBL16058382

SCHEMBL16058382

O=C(O)n1cccc(CCCOC2CCCCC2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 1/20 0.38
▸ NAAA Q02083 1/20 0.36
▸ FKBP1A P62942 3/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ AGTR2 P50052 1/20 0.33
▸ CNR1 P21554 2/20 0.32
▸ CNR2 P34972 2/20 0.32
▸ CYSLTR2 Q9NS75 2/20 0.32
▸ CYSLTR1 Q9Y271 1/20 0.32
▸ KDM4E B2RXH2 4/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ LMNA P02545 3/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057072 0.81 CYSLTR2 (0.46) NAAACYSLTR2CYSLTR1KDM4EALDH1A1
SCHEMBL16057607 0.80 CYSLTR2 (0.50) NAAACYSLTR2CYSLTR1KDM4E
SCHEMBL14975358 0.80 CYSLTR2 (0.50) NAAACYSLTR2CYSLTR1KDM4E
SCHEMBL16057735 0.80 CYSLTR2 (0.44) NAAACYSLTR2CYSLTR1KDM4EL3MBTL1
SCHEMBL16057719 0.79 CYSLTR2 (0.48) NAAACYSLTR2CYSLTR1KDM4ERAB9A
SCHEMBL16057274 0.78 SPHK1 (0.39) NAAA
SCHEMBL16057363 0.77 CHRM2 (0.36) NAAACYSLTR2CYSLTR1KDM4ELMNA
SCHEMBL16058140 0.73 HAO1 (0.39) NAAA
SCHEMBL16058352 0.72 BID (0.50) NAAANAMPTCYSLTR2CYSLTR1L3MBTL1
SCHEMBL14975000 0.72 BID (0.50) NAAANAMPTCYSLTR2CYSLTR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 TERT 4719/4885NAAA 1/4885FKBP1A 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback